



Financial Tear Sheet

Corporate Profile

Cambrex Corporation is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics.

We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.

Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage forms.

Primary IR Contact

Stephanie LaFiura
Investor Relations Associate
Phone: 201-804-3037
Fax: 201-804-9852
E-mail:
stephanie.lafiura@cambrex.com

Stock Performance

Symbol CBM (Common Stock)

Exchange NYSE (US Dollar)

Price \$53.50

Change (%) 0.00 (0.00%)

Volume 156,460

Data as of May 26, 2017 4:02 p.m. ET

Management

Steven M. Klosk President and Chief Executive Officer

Shawn P. Cavanagh Executive Vice President and Chief Operating Officer

Samantha M. Hanley Vice President, General Counsel and Secretary

Gregory P. Sargen Executive Vice President, Corporate Development and Strategy

Tom Vadaketh Executive Vice President and Chief Financial Officer

Recent Headlines & Events

There are currently no events scheduled.

Date	Title
May 17, 2017	CAMBREX INVESTS TO INCREASE PILOT SCALE API CAPACITY AT ITS HIGH POINT, NC FACILITY
May 15, 2017	Cambrex to Present at the 2017 UBS Global Healthcare Conference
May 04, 2017	Cambrex Reports First Quarter 2017 Financial Results

SEC Filings

Filing Date	Form
May 04, 2017	10-Q
May 04, 2017	8-K
May 02, 2017	4
May 02, 2017	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed.